Heinonen K, Mrózek K, Lawrence D, Arthur D C, Pettenati M J, Stamberg J, Qumsiyeh M B, Verma R S, MacCallum J, Schiffer C A, Bloomfield C D
Roswell Park Cancer Institute, Buffalo, New York, USA.
Br J Haematol. 1998 Jun;101(3):513-20. doi: 10.1046/j.1365-2141.1998.00714.x.
Isolated trisomy 11 is the third most common sole trisomy in de novo acute myeloid leukaemia (AML). However, only 49 cases have been published, and for only a fraction of these cases has full description of clinical and haematological features been provided. As a result, little is known about the clinical characteristics of de novo AML patients with solitary trisomy 11. We have identified 13 patients (0.9%) with isolated trisomy 11 among a total of 1496 consecutive adult patients successfully karyotyped as part of a prospective Cancer and Leukemia Group B (CALGB) cytogenetic study (CALGB 8461). Nine patients (69%) were over the age of 60 (range 29-73 years). Eight patients (62%) were diagnosed with AML of FAB M2 subtype, three patients (23%) had FAB M1 AML and one patient each had AML of FAB M0 and M7, respectively. Seven patients (54%) had high, >100 x 10(9)/l, platelet counts (median 102 x 10(9)/l; range 17-207 x 10(9)/l). All patients received CALGB induction therapy with standard doses of cytarabine and daunorubicin. Six patients (46%) achieved a complete remission (CR). The median CR duration was 17.5 months (range 8.7-49.8). Only one patient, who underwent bone marrow transplantation in first CR, continues in initial CR. The median survival was 14.3 months (range 0.5-50.7); only one patient survives. We conclude that de novo AML with isolated trisomy 11 is predominantly associated with older age, M2 and M1 FAB subtypes, high platelet count and few long-term disease-free survivals, although it is currently unknown whether isolated trisomy 11 constitutes an independent prognostic factor.
孤立性11号染色体三体是初发急性髓系白血病（AML）中第三常见的单纯性三体。然而，仅有49例病例被报道，其中只有一小部分病例对临床和血液学特征进行了全面描述。因此，对于初发孤立性11号染色体三体AML患者的临床特征知之甚少。在一项前瞻性癌症与白血病B组（CALGB）细胞遗传学研究（CALGB 8461）中，我们在1496例成功进行核型分析的连续成年患者中识别出13例（0.9%）孤立性11号染色体三体患者。9例（69%）患者年龄超过60岁（范围29 - 73岁）。8例（62%）患者被诊断为FAB M2亚型AML，3例（23%）为FAB M1 AML，各有1例患者分别为FAB M0和M7 AML。7例（54%）患者血小板计数高，>100×10⁹/L（中位数102×10⁹/L；范围17 - 207×10⁹/L）。所有患者均接受了CALGB标准剂量阿糖胞苷和柔红霉素诱导治疗。6例（46%）患者达到完全缓解（CR）。CR持续时间中位数为17.5个月（范围8.7 - 49.8）。仅1例在首次CR时接受骨髓移植的患者仍处于初始CR状态。中位生存期为14.3个月（范围0.5 - 50.7）；仅1例患者存活。我们得出结论，初发孤立性11号染色体三体AML主要与老年、FAB M2和M1亚型、高血小板计数以及长期无病生存者少相关，尽管目前尚不清楚孤立性11号染色体三体是否构成独立的预后因素。
